Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 16;4(3):103-107.
doi: 10.14744/hf.2022.2022.0036. eCollection 2023.

Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?

Sami Evirgen  1 , Bilger Cavus  1 , Suut Gokturk  1 , Raim Iliaz  1 , Zeynep Gozde Ozkan  2 , Bulent Baran  1 , Asli Ciftcibası Ormeci  1 , Ozlem Mutluay Soyer  1 , Cetin Karaca  1 , Kadir Demir  1 , Selman Fatih Besisik  1 , Arzu Poyanli  3 , Filiz Akyuz  1 , Sabahattin Kaymakoglu  1
Affiliations

Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?

Sami Evirgen et al. Hepatol Forum. .

Abstract

Background and aim: Radioembolization (RE) is a one of the palliative treatments that have been used to down stage and/or increase the survival time in intermediate-advanced stages of HCC. We aimed to evaluate the clinical impact of RE and the clinical use of the albumin-bilirubin (ALBI) score as a predictor for survival in HCC patients.

Materials and methods: Fifty-nine unresectable hepatocellular carcinoma (HCC) patients were enrolled. RE was performed in 28 of them (group 1) and 31 patients were followed up in the natural course (NC) (group 2). Patients were classified according to the Child-Pugh score (only cirrhotic patients), Barcelona clinic liver cancer (BCLC) staging, and ALBI scores were also calculated.

Results: All patients in Group 1 were cirrhotic and their BCLC stages were as follows: 60.7% stage B and 39.3% stage C. In Group 2, 83.9% of patients were cirrhotic and their BCLC stages were as follows: 9.7% stage B, 51.6% stage C, and 38.7% stage D. Mortality rates were 82% and 100% in Groups 1 and 2, respectively. The median overall survival (OS) was 13.5 months (95% CI: 10.4-16.6 months) and 4.5 months (95% CI: 3.5-5.5 months) in Groups 1 and 2, respectively (p=0.000). When RE was applied to patients with ALBI Grade 1 and 2, the median OS was statistically higher than in the NC group, respectively (p<0.001, p<0.001).

Conclusion: RE is an effective treatment method at the advanced stages of HCC. The ALBI score is a more useful and practical than the other prognostic tools.

Keywords: ALBI score; hepatocellular carcinoma; natural course; radioembolization.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Median Overall Survival graphic of patients who underwent RE versus to NC.
Figure 2
Figure 2
Median Overall Survival graphic according to Barcelona classification.
Figure 3
Figure 3
Median Overall Survival graphic of patients in BCLC-C patients who underwent RE versus to NC.
Figure 4
Figure 4
Median overall survival graphic of patients with ALBI grade 1 who underwent RE versus to NC (a), Median overall survival graphic of patients with ALBI grade 2 who underwent RE versus to NC (b).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin. 2020;70(1):7–30. - PubMed
    1. Lok AS, Seef LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–148. - PMC - PubMed
    1. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. - PubMed
    1. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7(9):1157–1167. - PMC - PubMed
    1. Farges O, Belghiti J. Primary tumours of the liver. Hepatobiliary and Pancreatic Surgery. In: James Garden O, editor. A Companion to Specialist Surgical Practice. Pennsylvania: WB Saunders; 2000.

LinkOut - more resources